MLYS Mineralys Therapeutics, Inc.
8-K Current Report
Filed: March 9, 2026
Health Care
Pharmaceutical PreparationsMineralys Therapeutics, Inc. (MLYS) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
AI Filing Analysis8-K
Item 7.01 · Regulation FD Disclosure
- • FDA accepted NDA for lorundrostat to treat adult hypertension (in combination with other antihypertensive drugs) — key regulatory milestone toward commercialization
- • NDA acceptance triggers PDUFA date assignment, moving lorundrostat closer to potential approval and market launch
Item 8.01 · Other Events
- • FDA accepted NDA for lorundrostat (hypertension combination therapy); PDUFA action date set for December 22, 2026 — key regulatory catalyst
- • Phase 2 Explore-OSA trial missed primary endpoint: lorundrostat 50mg failed to show clinically meaningful AHI reduction vs. placebo in obstructive sleep apnea
Other Mineralys Therapeutics, Inc. 8-K Filings
Get deeper insights on Mineralys Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.